Baena Cagnani 2006.

Methods	STUDY DESIGN: Parallel group LOCATION, NUMBER OF CENTRES: Multicentre, USA, South America DURATION OF STUDY: 12 months (6 month run‐in period reported, unclear treatment regime) CONCEALMENT OF ALLOCATION: Not reported COCHRANE QUALITY SCORE: B DESCRIBED AS RANDOMISED: Yes DESCRIBED AS DOUBLE BLIND: Yes METHOD OF RANDOMISATION WELL DESCRIBED/APPROPRIATE: Not reported METHOD OF BLINDING WELL DESCRIBED/APPROPRIATE: Not reported DESCRIPTION OF WITHDRAWALS/DROPOUTS: Not reported JADAD SCORE (5‐1): 2 TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT (presumed as most likely) COMPLIANCE: Not reported CONFOUNDERS: Not reported
Participants	N SCREENED: Unknown N RANDOMISED: 661 (eligible patients) N COMPLETED: Unknown M= unknown F= unknown MEDIAN AGE: Range ‐ males 5‐8.5 years; females 5‐7.5 years BASELINE DETAILS: Unknown INCLUSION CRITERIA: Mild persistent asthma; children EXCLUSION: Not reported
Interventions	1. Ciclesonide 50mcg OD 2. Ciclesonide 100cg OD 3. Placebo DELIVERY: MDI TREATMENT PERIOD: 12 months RESCUE: Not reported CO‐INTERVENTIONS PERMITTED: Not reported CO‐INTERVENTIONS: Not reported % on ICS baseline: Not reported
Outcomes	Growth velocity; adverse events; withdrawals
Notes	Unpublished conference abstract
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear